Jacques Morel
Université de Montpellier
H-index: 60
Europe-France
Top articles of Jacques Morel
Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open‐Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in …
Arthritis & Rheumatology
2024/4
Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and …
The Lancet Rheumatology
2024/3/1
Wan-Fai Ng
H-Index: 39
Jacques Morel
H-Index: 37
Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease
RMD open
2024/1/1
Jacques Morel
H-Index: 37
Recommendations of the French Society of Rheumatology for the management in current practice of patients with Polymyalgia Rheumatica
Joint Bone Spine
2024/4/5
Jacques Morel
H-Index: 37
E066 Baseline characteristics of patients initiating ixekizumab, secukinumab or a tumour necrosis factor inhibitor by country in the 24-month Prospective Psoriatic Arthritis …
2024/4/1
Jacques Morel
H-Index: 37
Vinod Chandran
H-Index: 46
Le catastrophisme dans la polyarthrite rhumatoïde: cohorte bicentrique CRIC de 231 patients suivis 1 an
Revue du Rhumatisme
2023/12/1
AB1115 STUDY DESIGN AND FULL BASELINE SAMPLE CHARACTERISTICS OF PATIENTS FROM THE 24-MONTH MULTINATIONAL PROSPECTIVE PSORIATIC ARTHRITIS OBSERVATIONAL STUDY OF PERSISTENCE OF …
2023/6/1
Efficacité et tolérance d’une association de traitements ciblés indiqués pour l’asthme et pour les rhumatismes inflammatoires chroniques
Revue du Rhumatisme
2023/12/1
POS1068 HUMORAL IMMUNE RESPONSE TO 13 VALENT-CONJUGATE AND 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINES IN RA PATIENTS TREATED WITH ABATACEPT: RESULTS OF THE OPEN RANDOMIZED …
2023/6/1
Étude observationnelle prospective de 24 mois de la persistance du traitement chez des patients atteints de rhumatisme psoriasique (PRO-SPIRIT)–conception de l’étude et …
Revue du Rhumatisme
2023/12/1
POS0182 RISK-BENEFIT ASSESSMENT OF THE USE OF RITUXIMAB FOR RHEUMATOID ARTHRITIS IN REAL LIFE: FINDINGS FROM 1984 PATIENTS FROM THE FRENCH AUTOIMMUNITY AND RITUXIMAB REGISTRY
2023/6/1
Le dépistage systématique des multimorbidités entraîne une augmentation de la prise de médicaments préventifs des comorbidités et une diminution du taux d’hospitalisation
Revue du Rhumatisme
2023/12/1
POS0651 VACCINATION RATE AND FACTORS ASSOCIATED WITH NON-VACCINATION IN AXIAL SPONDYLOARTHRITIS: A CROSS SECTIONAL PROSPECTIVE MULTICENTRIC OBSERVATIONAL STUDY
2023/6/1
Recommandations du GEFA pour l’utilisation des immunosuppresseurs et thérapies ciblées dans l’artérite à cellules géantes
La Revue de Médecine Interne
2023/12/1
Chronological interplay, clinical features, and treatments among patients with cancer and primary Sjögren’s syndrome
Cancer Immunology, Immunotherapy
2023/12
Jacques Morel
H-Index: 37
Christian Jorgensen
H-Index: 8
POS0533 RISK OF SEVERE INFECTIONS IN IMMUNE MEDIATED INFLAMMATORY DISEASES WITH IMMUNOGLOBULIN DEFICIENCY UNDER RITUXIMAB THERAPY
2023/6/1
Nouveautés dans l’imagerie du pied au cours de la Polyarthrite Rhumatoïde
2023/11/28
Jacques Morel
H-Index: 37
Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry
Rheumatology
2023/9/19
Jacques Morel
H-Index: 37
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
Annals of the Rheumatic Diseases
2023/6/1
Artritis reumatoide del adulto: epidemiología, clínica y diagnóstico
2023/9/1
